The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Improving the therapeutic index of anthracycline chemotherapy: Focus on liposomal doxorubicin (Myocet™)
Open accessAbstract
Anthracyclines are valuable cytotoxic agents in cancer treatment. However, their usefulness is limited by cumulative dose-dependent cardiotoxicity that may manifest as life-threatening congestive heart failure. To avoid cardiotoxicity, the use of doxorubicin is typically capped at a safe cumulative dose. Liposomal formulations may reduce cardiac risks whilst maintaining anti-cancer efficacy. Efficacy and safety studies of non-pegylated liposomal doxorubicin (NPLD) in metastatic breast cancer (MBC) are reviewed, along with studies that examine efficacy and cardiac tolerability in combination with newer agents such as paclitaxel and trastuzumab. These show that cardiac safety of liposomal doxorubicin is similar to that of epirubicin in cumulative dose, but that the formulation, unlike epirubicin, has similar anti-cancer efficacy to doxorubicin at equimolar doses. Liposomal doxorubicin may have a better therapeutic index than non-liposomal anthracyclines. This justifies further studies in patients where cumulative cardiotoxicity is a concern, as does study of its use with other potentially cardiotoxic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500 · cited 1×
“The incidence of cardiotoxicity was similar, irrespective of which anthracycline used, although the number of patients treated with epirubicin was small.(19) This increased risk of cardiotoxicity has mandated a special warning for users in the product labelling of Herceptin , stating that the combination of trastuzuma…”
BackgroundTrastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Risk Factors for Doxorubicin-lnduced Congestive Heart Failure
VON HOFF, D. D., LAYARD, M. W., BASA, P., DAVIS, H. L., VON HOFF, A. L., ROZENCWEIG, M., & MUGGIA, F. M. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-5-710 · Cited by 2,391
Rowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Doxorubicin-Induced Cardiomyopathy
Singal, P. K., & Iliskovic, N. (1998) · New England Journal of Medicine · doi:10.1056/nejm199809243391307 · Cited by 1,845
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Late Cardiac Effects of Doxorubicin Therapy for Acute Lymphoblastic Leukemia in Childhood
Lipshultz, S. E., Colan, S. D., Gelber, R. D., Perez-Atayde, A. R., Sallan, S. E., & Sanders, S. P. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241205 · Cited by 1,404
Buzdar, A. U., Ibrahim, N. K., Francis, D., Booser, D. J., Thomas, E. S., Theriault, R. L., Pusztai, L., Green, M. C., Arun, B. K., Giordano, S. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.032 · Cited by 1,171
Cardiac Toxicity 4 to 20 Years After Completing Anthracycline Therapy
Steinherz, L. J. (1991) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1991.03470120074036 · Cited by 989
Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion
LEGHA, S. S., BENJAMIN, R. S., MACKAY, B., EWER, M., WALLACE, S., VALDIVIESO, M., RASMUSSEN, S. L., BLUMENSCHEIN, G. R., & FREIREICH, E. J. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-2-133 · Cited by 763
Anthrazykline in der Krebstherapie: Ein Überblick
Hortobágyi, G. N. (1997) · Drugs · doi:10.2165/00003495-199700544-00003 · Cited by 678
Batist, G., Ramakrishnan, G., Rao, C. S., Chandrasekharan, A., Gutheil, J., Guthrie, T., Shah, P., Khojasteh, A., Nair, M. K., Hoelzer, K., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.5.1444 · Cited by 669
Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.
Swain, S. M., Whaley, F. S., Gerber, M. C., Weisberg, S., York, M., Spicer, D., Jones, S. E., Wadler, S., Desai, A., Vogel, C., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1318 · Cited by 664
Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Rolski, J., Chan, A., Mackey, J., Liu, M., Pinter, T., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.sabcs-09-62 · Cited by 553
Jones, S. E., Savin, M. A., Holmes, F. A., O'Shaughnessy, J. A., Blum, J. L., Vukelja, S., McIntyre, K. J., Pippen, J. E., Bordelon, J. H., Kirby, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5391 · Cited by 538
Harris, L., Batist, G., Belt, R., Rovira, D., Navari, R., Azarnia, N., Welles, L., Winer, E., & TLC D‐99 Study Group (2002) · Cancer · doi:10.1002/cncr.10201 · Cited by 512
Neuregulins Promote Survival and Growth of Cardiac Myocytes
Zhao, Y.-Y., Sawyer, D. R., Baliga, R. R., Opel, D. J., Han, X., Marchionni, M. A., & Kelly, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.17.10261 · Cited by 504
Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy
Gabizon, A. A. (2001) · Cancer Investigation · doi:10.1081/cnv-100103136 · Cited by 458
Anthracycline Cardiotoxicity: From Bench to Bedside
Gianni, L., Herman, E. H., Lipshultz, S. E., Minotti, G., Sarvazyan, N., & Sawyer, D. B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9401 · Cited by 454
Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity
Aries, A., Paradis, P., Lefebvre, C., Schwartz, R. J., & Nemer, M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401833101 · Cited by 296
Ranson, M. R., Carmichael, J., O'Byrne, K., Stewart, S., Smith, D., & Howell, A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.10.3185 · Cited by 293
Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.
Ryberg, M., Nielsen, D., Skovsgaard, T., Hansen, J., Jensen, B. V., & Dombernowsky, P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3502 · Cited by 289
Swain, S. M., Whaley, F. S., Gerber, M. C., Ewer, M. S., Bianchine, J. R., & Gams, R. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1333 · Cited by 269
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub4 · Cited by 265
Clinical spectrum of anthracycline antibiotic cardiotoxicity.
Bristow, M. R., Billingham, M. E., Mason, J. W., & Daniels, J. R. (1978) · PubMed · Cited by 250
Gabizon, A., Shiota, R., & Papahadjopoulos, D. (1989) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/81.19.1484 · Cited by 219
Kuramochi, Y., Cote, G. M., Guo, X., Lebrasseur, N. K., Cui, L., Liao, R., & Sawyer, D. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408662200 · Cited by 176
Acute arrhythmogenicity of doxorubicin administration
Steinberg, J. S., Cohen, A. J., Wasserman, A. G., Cohen, P., & Ross, A. M. (1987) · Cancer · doi:10.1002/1097-0142(19870915)60:6<1213::aid-cncr2820600609>3.0.co;2-v · Cited by 171
Chan, S. Y. T., Davidson, N. G. P., Juozaitytė, E., Erdkamp, F., Pluzanska, A., Azarnia, N., & Lee, L. W. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh393 · Cited by 167
de Korte, M. A., de Vries, E. G. E., Lub-de Hooge, M. N., Jager, P. L., Gietema, J. A., van der Graaf, W. T. A., Sluiter, W. J., van Veldhuisen, D. J., Suter, T. M., Sleijfer, D. T., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.06.024 · Cited by 160
Cardiotoxicity of doxorubicin and other anthracycline derivatives
Jain, D. (2000) · Journal of Nuclear Cardiology · doi:10.1067/mnc.2000.103324 · Cited by 149
Liposome technology and the development of Myocet™ (liposomal doxorubicin citrate)
Swenson, C. E., Perkins, W. R., Roberts, P., & Janoff, A. S. (2001) · The Breast · doi:10.1016/s0960-9776(01)80001-1 · Cited by 136
ErbB2 Pathways in Heart and Neural Diseases
Garratt, A. N., Özcelik, C., & Birchmeier, C. (2003) · Trends in Cardiovascular Medicine · doi:10.1016/s1050-1738(02)00231-1 · Cited by 122
Hamilton, A. L., Biganzoli, L., Coleman, R. E., Mauriac, L., Hennebert, P., Awada, A. H., Nooij, M., Beex, L. V. A. M., Piccart, M. J., Hoorebeeck, I. V., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf157 · Cited by 105
Anthracyclines in haematology: preclinical studies, toxicity and delivery systems
Richardson, D. S., & Johnson, S. A. (1997) · Blood Reviews · doi:10.1016/s0268-960x(97)90020-5 · Cited by 103
Rougier, P. R., Lepille, D., Bennouna, J., Marre, A., Ducreux, M. P., Mignot, L., Hua, A., & Méry-Mignard, D. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf259 · Cited by 86
Seymour, L., Bramwell, V., & Moran, L. A. (1999) · PubMed · Cited by 78
Smith, D. H., Adams, J. R., Johnston, S. R. D., Gordon, A., Drummond, M., & Bennett, C. L. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf275 · Cited by 76
Cortés, J., Cosimo, S. D., Climent, M. A., Cortés-Funes, H., Lluch, A. M., Gascón, P., Mayordomo, J. I., Gil, M. G., Benavides, M., Cirera, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1113 · Cited by 60
Untch, M., Eidtmann, H., du Bois, A., Meerpohl, H. G., Thomssen, C., Ebert, A. D., Harbeck, N., Jackisch, C., Heilmann, V., Emons, G., et al. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.011 · Cited by 59
Speyer, J. L., Green, M. D., Dubin, N., Blum, R. H., Wernz, J., Roses, D. F., Sanger, J. J., & Muggia, F. M. (1985) · The American Journal of Medicine · doi:10.1016/0002-9343(85)90395-x · Cited by 52
Berrak, S. G., Ewer, M. S., Jaffe, N., Pearson, P., Ried, H. L., Zietz, H. A., & Benjamin, R. S. (2001) · Oncology Reports · doi:10.3892/or.8.3.611 · Cited by 41
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
van Dalen, E. C., Michiels, E. M. C., Caron, H. N., & Kremer, L. C. M. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005006.pub2 · Cited by 41
Mrózek, E., Rhoades, C. A., Allen, J., Hade, E. M., & Shapiro, C. L. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi209 · Cited by 31
A phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin.
de Vries, E. G. E., Greidanus, J. W., Mulder, N. H., Nieweg, M. B., Postmus, P. E., Schipper, D. L., Sleijfer, D. T., Uges, D. R. A., & Willemse, P. H. B. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.9.1445 · Cited by 23
Cited by
Analysis of nanoparticle delivery to tumours
Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218
Liposomal Formulations in Clinical Use: An Updated Review
Bulbake, U., Doppalapudi, S., Kommineni, N., & Khan, W. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9020012 · Cited by 2,156
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Recent advancements in liposome technology
Filipczak, N., Pan, J., Yalamarty, S. S. K., & Torchilin, V. P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.022 · Cited by 592
Metadata
- Authors
- Leonard, R. C. F., Williams, S., Tulpule, A., Levine, A. M., & Oliveros, S.
- Venue
- The Breast
- Publisher
- Elsevier BV
- Published
- 2009-08
- Volume
- 18
- Issue
- 4
- Pages
- 218-224
- ISSN
- 0960-9776 (ISSN-L)
- OpenAlex
- W2005464092
- Cited by
- 257
- References
- 47
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.